ARTICLE | Company News
Amgen adds stroma-targeted therapy via Molecular Partners deal
December 21, 2018 7:26 PM UTC
Through a deal with Molecular Partners AG (SIX:MOLN) giving it rights to programs targeting the tumor stroma, Amgen Inc. (NASDAQ:AMGN) will expand its immuno-oncology toolbox beyond tumor antigen-targeted therapies.
On Dec. 19, Amgen received exclusive, worldwide rights to develop and commercialize tumor stroma-targeted MP0310 from Molecular Partners for $50 million up front and up to $497 million in development, regulatory and commercial milestones...